Table 2.
Overall survival of the whole cohort at 3 years by surgical specimen (after chemotherapy) immune biomarker expression and overall survival for the subgroup of patients that failed to achieve pCR (no-pCR group)
| Evt/N | 3yr-OS | 95% CI | ||
|---|---|---|---|---|
| All patients | ||||
| PD-L1 | p = 0.0055 | |||
| Negative (IC0) | 4/38 | 89.4% | 70.6–96.5 | |
| Positive (IC1/2/3) | 9/28 | 57.4% | 33.2–75.5 | |
| TILs | p = 0.6312 | |||
| 0–10% | 6/35 | 79.6% | 57.0–91.2 | |
| > 10% | 7/31 | 72.5% | 50.6–85.9 | |
| TIM-3 | p = 0.0840 | |||
| < 1% | 2/21 | 93.8% | 63.2–99.1 | |
| ≥ 1% | 11/45 | 67.0% | 48.0–80.5 | |
| TIM-3 | p = 0.0274 | |||
| 0–4% | 5/44 | 87.1% | 68.6–95.1 | |
| ≥ 5% | 8/22 | 58.0% | 33.1–76.4 | |
| LAG-3 | p = 0.7750 | |||
| 0 | 2/11 | 88.9% | 43.3–98.4 | |
| > 0 | 11/55 | 73.5% | 56.9–84.5 | |
| PD-L1 and TIM-3 | p = 0.0020 | |||
| Others | 7/54 | 84.6% | 68.5–92.9 | |
| PD-L1+/TIM-3+ | 6/12 | 45.5% | 16.7–70.7 | |
| No-pCR group | ||||
| PD-L1 | p = 0.1186 | |||
| Negative (IC0) | 3/14 | 84.6% | 51.2–95.9 | |
| Positive (IC1/2/3) | 8/23 | 58.0% | 33.0–76.5 | |
| TILs | p = 0.8008 | |||
| 0–10% | 5/16 | 72.0% | 41.1–88.6 | |
| > 10% | 6/21 | 65.7% | 38.8–83.0 | |
| TIM-3 | p = 0.0702 | |||
| 0–4% | 3/20 | 88.7% | 61.4–97.1 | |
| ≥ 5% | 8/17 | 50.0% | 24.5–71.0 | |
| PD-L1 and TIM-3 | p = 0.0479 | |||
| Others | 5/25 | 81.3% | 57.3–92.6 | |
| PD-L1+/TIM-3+ | 6/12 | 45.5% | 16.7–70.7 | |